Table 1 Patient characteristics. Data are displayed in means (standard error of the mean)
From: The effects of molar activity on [18F]FDOPA uptake in patients with neuroendocrine tumors
Group 1 (n = 22) | Group 2 (n = 9) | Group 3 (n = 18) | |
|---|---|---|---|
Age (years) | 1st scan: 56 (4) | 1st scan: 54 (4) | 1st scan: 64 (3) |
2nd scan: 58 (4) | 2nd scan: 57 (4) | 2nd scan: 65 (3) | |
Sex (male, %) | 53% | 50% | 41% |
On somatostatin analogue treatment: | |||
At first scan (%) | 4.5% | 0% | 44% |
At second scan (%) | 0% | 11% | 44% |
Change of medication (%) | 4.5% | 11% | 11% (1 stopped, 1 started therapy) |
Total number of lesions evaluated | 1st scan: 0 | 1st scan: 9 | 1st scan: 56 |
2nd scan: 0 | 2nd scan: 9 | 2nd scan: 56 | |
Total number of lesions | 1st scan: 0 | 1st scan: 10 | 1st scan: 78 |
2nd scan: 0 | 2nd scan: 10 | 2nd scan: 90 | |
Interval surgery (n) | 1 (cholecystectomy) | 0 | 0 |
NET primary site (%) | GI-tract 68% | GI-tract 44% | GI-tract 65% |
Pancreas 5% | Thyroid 22% | Pancreas 6% | |
Thyroid 5% | Lung 11% | Head and neck 6% | |
Lung 5% | Adrenal 11% | Lung 12% | |
Unknown 16% | Paraganglioma 11% | Adrenal 6% | |
Ovary 6% | |||
NET grade (%) | Grade 1 84% | Grade 1 33% | Grade 1 71% |
Undefined 16% | Grade 2 22% | Grade 2 12% | |
Undefined 44% | Undefined 18% | ||